Insider and congress filings
Alnylam Pharmaceuticals, Inc. (ALNY)
About Alnylam Pharmaceuticals, Inc.
from the company's filings and listing- Exchange
- NASDAQ
- Sector
- Healthcare
- Industry
- Biotechnology
- Chief executive
- Yvonne L. Greenstreet
- Employees
- 2,500
- Listed since
- Jun 1, 2004
- Market value
- $34.5B
- Price to earnings
- 42.3
- Earnings per share
- $6.06
- Dividend yield
- -
Earnings
6 reported quarters · next on Oct 29, 2026| Quarter | EPS | EPS expected | Revenue | Revenue expected | Result |
|---|---|---|---|---|---|
| Q2 FY2026reported Jul 30, 2026 | $1.21 | $1.63 | $1.3B | $1.3B | EPS missRevenue miss |
| Q1 FY2026reported Apr 30, 2026 | $1.51 | $0.87 | $1.2B | $1.1B | EPS beatRevenue beat |
| Q4 FY2025reported Feb 12, 2026 | $0.82 | $1.16 | $1.1B | $1.1B | EPS missRevenue miss |
| Q3 FY2025reported Oct 30, 2025 | $1.84 | $0.56 | $1.2B | $959.4M | EPS beatRevenue beat |
| Q2 FY2025reported Jul 31, 2025 | -$0.51 | -$0.54 | $773.7M | $662.9M | EPS beatRevenue beat |
| Q1 FY2025reported May 1, 2025 | -$0.44 | -$0.89 | $594.2M | $585.1M | EPS beatRevenue beat |
Actual against the consensus estimate at the time. A flag marks a beat or a miss of more than 1.5% either way; inside that band the quarter is in line. A flag marked GAAP compares a GAAP figure the company reported with an adjusted consensus, two different measures, so a one-time gain or charge can move it either way; basis unverified means we could not classify the reported figure. A flag reads n/a only when a number is missing. An estimate is a forecast made by analysts, not a company target.
Executive pay
as filed for 2025 · proxy filed Apr 6, 2026| Executive | Salary | Stock awards | Other | Total |
|---|---|---|---|---|
| Yvonne L. Greenstreet, M.D.Chief Executive Officer (principal executive officer) | $1.4M | $5.5M | $8.0M | $14.9M |
| Jeffrey V. PoultonExecutive Vice President, Chief Financial Officer (pri | $724K | $4.0M | $2.2M | $6.9M |
| Bryan A. SupranExecutive Vice President, Chief Legal Officer and Secr | $190K | $6.0M | $656K | $6.8M |
| Pushkal Garg, M.D.Executive Vice President, Chief Research and Developme | $768K | $3.7M | $2.0M | $6.5M |
| Tolga TangulerExecutive Vice President, Chief Commercial Officer | $698K | $3.7M | $1.7M | $6.1M |
The summary compensation table from the 2025 proxy statement, current executives only. Read the filing
Institutional holders
13F positions as of Jun 30, 2026| Holder | Value | Shares | Change | Of company |
|---|---|---|---|---|
| FMR LLC | $4.5B | 15,023,962 | +3.1% | 11.28% |
| Capital World Investors | $3.4B | 11,144,846 | +3.2% | 8.36% |
| Blackrock, Inc. | $3.3B | 10,907,675 | +4.4% | 8.19% |
| Capital Research Global Investors | $2.9B | 9,750,699 | +3.0% | 7.32% |
| Vanguard Portfolio Management LLC | $2.0B | 6,538,390 | +0.7% | 4.91% |
| Vanguard Capital Management LLC | $1.8B | 6,029,478 | +1.4% | 4.53% |
| T. Rowe Price Investment Management, Inc. | $1.7B | 5,642,173 | +8.6% | 4.23% |
| Invesco Ltd. | $1.1B | 3,754,318 | +34.9% | 2.82% |
| State Street Corp | $1.1B | 3,555,689 | +7.0% | 2.67% |
| Geode Capital Management, LLC | $791.3M | 2,635,840 | -0.9% | 1.98% |
| Jpmorgan Chase & Co | $785.3M | 2,675,517 | -57.7% | 2.01% |
| Baillie Gifford & Co | $734.5M | 2,439,889 | -2.2% | 1.83% |
A 13F reports long US equity positions 45 days after the quarter ends, so these are positions as they stood on Jun 30, 2026. For a manager's whole book see the fund directory.
GetSignal watches Form 4 and STOCK Act filings and pushes each one to your phone as it is published, with the history behind it. Free on iOS and Android.
Open-market insider trades
10 filings of 376 on record| Insider | Action | Shares | Price | Value | Trade date | Delay |
|---|---|---|---|---|---|---|
| David E. I. PyottDirector | Sold · scheduled · 5 lines | 3,830 | $299.18 | $1.1M | Jun 1, 2026 | 2d |
| Melissa McLaughlinChief Human Resources Officer | Sold · scheduled · 9 lines | 1,624 | $319.59 | $519K | Apr 2, 2026 | 5d |
| Melissa McLaughlinChief Human Resources Officer | Sold · scheduled · 5 lines | 2,286 | $330.42 | $755K | Apr 6, 2026 | 1d |
| Jeffrey V. PoultonEVP, Chief Financial Officer | Sold · 7 lines | 1,650 | $322.70 | $532K | Mar 4, 2026 | 2d |
| Pushkal GargEVP Chief R&D | Sold · scheduled · 4 lines | 2,404 | $323.96 | $779K | Mar 5, 2026 | 1d |
| Yvonne GreenstreetChief Executive Officer | Sold · 5 lines | 2,194 | $322.66 | $708K | Mar 4, 2026 | 2d |
| Kevin Joseph FitzgeraldCSO & EVP, Head of Research | Sold · scheduled · 4 lines | 658 | $323.98 | $213K | Mar 5, 2026 | 1d |
| Pushkal GargEVP Chief R&D | Sold · scheduled · 4 lines | 956 | $321.84 | $308K | Mar 4, 2026 | 2d |
| Kevin Joseph FitzgeraldCSO & EVP, Head of Research | Sold · scheduled · 8 lines | 633 | $323.08 | $205K | Mar 4, 2026 | 2d |
| Tolga TangulerEVP, Chief Commercial Officer | Sold · 7 lines | 2,203 | $323.27 | $712K | Mar 4, 2026 | 2d |
One row is one filing. A filing that reported its trade in several tranches is summed, priced at the weighted average, and marked with its line count.
Congress trades in ALNY
13 disclosures of 13 on record · median 29d of the 45 allowed| Member | Type | Action | Amount disclosed | Since the trade | Trade date | Disclosed | Delay |
|---|---|---|---|---|---|---|---|
| Jefferson Shreve | Stock | Sale | $15,001 - $50,000 | -3.5%S&P +31.7% · vs S&P 500 -35.2% | May 12, 2025 | Jun 22, 2025 | 41d |
| Josh GottheimerJoint | Stock | Purchase | $1,001 - $15,000 | +32.3%S&P +60.1% · vs S&P 500 -27.8% | Jan 11, 2024 | Feb 15, 2024 | 35d |
| Josh GottheimerJoint | Stock | Sale | $1,001 - $15,000 | +42.6%S&P +55.2% · vs S&P 500 -12.7% | Jan 29, 2024 | Feb 15, 2024 | 17d |
| Josh GottheimerJoint | Stock | Sale | $1,001 - $15,000 | +51.0%S&P +65.1% · vs S&P 500 -14.1% | Dec 11, 2023 | Jan 7, 2024 | 27d |
| Daniel S. Goldman | Stock | Purchase | $15,001 - $50,000 | +29.2%S&P +88.5% · vs S&P 500 -59.3% | Mar 6, 2023 | Apr 17, 2023 | 42d |
| Daniel S. Goldman | Stock | Sale | $15,001 | +14.0%S&P +87.7% · vs S&P 500 -73.7% | Jan 31, 2023 | Feb 24, 2023 | 24d |
| Ro Khanna | Stock | Exchange | $1,001 - $15,000 | +11.7%S&P +99.7% · vs S&P 500 -88.0% | Jan 4, 2023 | Jan 6, 2023 | 2d |
| Josh GottheimerJoint | Stock | Purchase | $1,001 - $15,000 | +22.4%S&P +105.9% · vs S&P 500 -83.4% | Sep 28, 2022 | Oct 16, 2022 | 18d |
| Josh GottheimerJoint | Stock | Sale | $1,001 - $15,000 | +90.4%S&P +113.0% · vs S&P 500 -22.6% | Nov 13, 2020 | Dec 9, 2020 | 26d |
| Josh GottheimerJoint | Stock | Purchase | $1,001 - $15,000 | +130.1%S&P +187.8% · vs S&P 500 -57.7% | Apr 6, 2020 | May 13, 2020 | 37d |
| Ro Khanna | Stock | Purchase | $1,001 - $15,000 | +282.0%S&P +178.4% · vs S&P 500 +103.5% | Jun 3, 2019 | Jul 11, 2019 | 38d |
| Josh GottheimerJoint | Stock | Sale | $1,001 - $15,000 | +228.3%S&P +175.9% · vs S&P 500 +52.4% | Oct 18, 2018 | Nov 16, 2018 | 29d |
| Josh GottheimerJointFiled late | Stock | Purchase | $1,001 - $15,000 | +156.3%S&P +178.8% · vs S&P 500 -22.4% | Jun 1, 2018 | Oct 2, 2018 | 123d |
Since the trade: the stock's move from the trade date to the latest close we hold, as of Sep 10, 2026, an estimate, with the S&P 500 over the same window and the difference against it. The figures describe the stock after the trade, not the member's result: the filing carries a band, not a fill, and a sale keeps the same sign, so a positive figure after a sale means the stock kept rising. An option row carries the underlying stock's move. A row marked n/a has no market price. Not investment advice.
Awards, option exercises and gifts (13)
| Insider | Event | Shares | Date |
|---|---|---|---|
| Benjamin CravattDirector | Stock award | 4,393 | Jun 1, 2026 |
| David E. I. PyottDirector | Option exercise | 3,830 | Jun 1, 2026 |
| Margaret A. HamburgDirector | Stock award | 2,112 | May 20, 2026 |
| Olivier BrandicourtDirector | Stock award | 2,112 | May 20, 2026 |
| Dennis A. AusielloDirector | Stock award | 2,112 | May 20, 2026 |
| David E. I. PyottDirector | Stock award | 2,112 | May 20, 2026 |
| Amy W. SchulmanDirector | Stock award | 2,640 | May 20, 2026 |
| Peter N. KelloggDirector | Stock award | 2,112 | May 20, 2026 |
| Colleen F. ReitanDirector | Stock award | 2,112 | May 20, 2026 |
| Stuart A. ArbuckleDirector | Stock award | 2,112 | May 20, 2026 |
| Charles Elliott SigalDirector | Stock award | 2,112 | May 20, 2026 |
| Amy W. SchulmanDirector | Option exercise | 11,250 | May 13, 2026 |
| Melissa McLaughlinChief Human Resources Officer | Form 4 | 3,567 | Mar 25, 2026 |
Awards, option exercises, shares withheld to cover tax and gifts all file on the same form as a purchase or a sale. None of them is a decision to trade, so they sit here rather than beside the ones that are.
Questions
Are insiders buying or selling ALNY?
Across the 10 most recent open-market filings shown here, 0 were purchases and 10 were sales. 7 were scheduled in advance under a Rule 10b5-1 plan.
Which members of Congress have traded ALNY?
Jefferson Shreve, Josh Gottheimer, Daniel S. Goldman, Ro Khanna disclosed ALNY transactions in the filings shown here.
Is ALNY in the S&P 500 or the Nasdaq 100?
Alnylam Pharmaceuticals, Inc. is a current member of the Nasdaq 100, per the membership list we hold as of Sep 10, 2026. Current members of either index get a page here whatever their filing history.
How quickly are ALNY trades disclosed?
Insider filings on this page reached the public a median of 2 days after the transaction, against the two business days Form 4 allows. Congressional disclosures took a median of 29 days, against the 45 the STOCK Act allows.
How to read a Form 4
A DECISION THE INSIDER MADE
COMPENSATION PLUMBING
Congress rows disclose a value range rather than an exact amount, and the STOCK Act allows up to 45 days to report. Full sourcing and the limits of this data are on the methodology page. A filing is a record of a transaction, not a signal, and nothing here is investment advice.
Data as of Sep 10, 2026.